ALLMedicine™ Inclusion Body Myositis Center

May 18th, 2022 - Pain is commonly reported in people living with myositis. This study assesses the presence of pain in the subtypes of myositis as well frequency of opioid and non-opioid pain medication use. A survey was developed and distributed by Myositis Suppo...

Apr 9th, 2022 - Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases. All forms of myosi...

Mar 30th, 2022 - To perform a systematic literature review (SLR) on the association of common variable immunodeficiency (CVID) and rare and complex connective tissue and musculoskeletal diseases, namely systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), ...

Mar 29th, 2022 - Patients with neuromuscular disorders display different type of symptoms depending on the type of pathology. Diseases like facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD2b), sporadic inclusion body myositis (SIBM) or Po...

Mar 29th, 2022 - Sporadic inclusion body myositis (IBM) is a debilitating disease which leads to impaired ambulation and loss of hand function. Yale IBM Registry (IBMR) was launched in November 2016 to address the knowledge gap in IBM natural history data. The reg...

Mar 29th, 2022 - Patients with neuromuscular disorders display different type of symptoms depending on the type of pathology. Diseases like facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD2b), sporadic inclusion body myositis (SIBM) or Po...

Mar 15th, 2022 - An open-label, ascending dose study for adult patients with inclusion body myositis (IBM).

Jan 26th, 2022 - Inclusion Body Myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over age 50 years, with an annual incidence estimated at 2.2 to 7.9 per million. IBM causes both proximal and distal muscle weakness,...

Nov 18th, 2021 - A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of sIBM

Sep 2nd, 2021 - The main objective of this study is to evaluate the tolerance of escalating doses of ADSVF, one month after intramuscular injection in the finger flexors, in the non-dominant forearm. The second objective of this study is to evaluate the efficacy ...

May 13th, 2022 - All patients with idiopathic inflammatory myopathies (IIM) should be screened for swallowing difficulties, according to the first evidence-based guideline to be produced. The guideline, which has been developed by a working group of the British So...

Jan 5th, 2021 - A patient asks an advanced practice registered nurse (APRN) to approve them for "medical marijuana." What are the clinician's responsibilities? The first hurdle is legal. In 18 states, an APRN has the legal authority to certify a patient to use ma...

Dec 4th, 2020 - Gayatri R. Rao, MD, JD Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma, the regulatory agency ...

Sep 13th, 2019 - Recent sunburn was associated with the development of dermatomyositis (DM), data from a U.S. national patient registry suggested. Compared with patients diagnosed with other forms of myositis, those who reported having had two or more sunburns in ...

Feb 27th, 2019 - Amyloid PET imaging may help to accurately identify inclusion body myositis and distinguish it from polymyositis, which could potentially avoid misdiagnosis and unnecessary immunosuppressive medication, according to findings from a small prospecti.